Parkinson's disease: Diagnosis and treatment

American Family Physician

Volumn 74, Issue 12, 2006, Pages

  Rao, Shobha S ^a   Hofmann, Laura A ^a   Shakil, Amer ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE; BENZATROPINE MESILATE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE MESILATE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; TYRAMINE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEMENTIA; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DIZZINESS; DRUG INDUCED DISEASE; DYSKINESIA; EDEMA; EYE DISEASE; HALLUCINATION; HEADACHE; HEART MUSCLE FIBROSIS; HUMAN; HYPOTENSION; INSOMNIA; LIVER FAILURE; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; URINE; URINE RETENTION; XEROSTOMIA;

ALGORITHMS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 33845531563     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240-4.
2. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005;353:1021-7.
3. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(11 suppl 5):S1-88.
4. Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol 2004;3:466-74.
5. Italian Neurological Society, Italian Society of Clinical Neurophysiology. Guidelines for the treatment of Parkinson's disease 2002. The diagnosis of Parkinson's disease. Neurol Sci 2003;(24 suppl 3):S157-64.
6. Rao G, Fisch L, Srinivasan S, D'Amico F, Okada T, Eaton C, et al. Does this patient have Parkinson disease? JAMA 2003;289:347-53.
7. Agency for Healthcare Research and Quality. Diagnosis and treatment of Parkinson's disease: a systematic review of the literature. Accessed June 19, 2006, at: http://www.ahrq.gov/clinic/epcsums/parksum.htm.
8. Seritan AL, Mendez MF, Silverman DH, Hurley RA, Taber KH. Functional imaging as a window to dementia: corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2004;16:393-9.
9. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-75.
10. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al., for the Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
11. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
12. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
13. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18;738-50.
14. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-7.
15. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-39.
16. Samii A, Ransom BR. Movement disorders: overview and treatment options. P&T 2005;30:228-38.
17. Shannon KM, Bennett JP Jr, Friedman JH, for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease [Published correction appears in Neurology 1998;50:838]. Neurology 1997;49:724-8.
18. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al., for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease [Published correction appears in Neurology 1997;49:1484]. Neurology 1997;49:393-9.
19. Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malagu S, et al., for the Pergolide Monotherapy Study Group. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Neurology 1999;53:573-9.
20. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.
21. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-8.
22. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593.
23. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.
24. Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000;(2):CD002261.
25. Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001;(1):CD001516.
26. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004;(4):CD004554.
27. Rascol O, Brooks DJ, Melamed E, et al. A comparative randomised study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson's disease (PD) patients with motor fluctuations (the LARGO study). 56th Annual Meeting of the American Academy of Neurology, San Francisco, Calif., 2004. Abstract S38.004. Neurology 2004;62(7 suppl 5):A1-626.
28. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-3.
29. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95.
30. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson disease (an evidence-based review). Accessed June 19, 2006, at: http://www.aan.com/professionals/practice/guidelines/pda/ eval_dementia_pd.pdf.
31. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-92.
32. Deane KH, Ellis-Hill C, Playford ED, Ben-Shlomo Y, Clarke CE. Occupational therapy for patients with Parkinson's disease. Cochrane Database Syst Rev 2001;(2):CD002813.
33. Deane KH, Jones D, Playford ED, Ben-Shlomo Y, Clark CE. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2001;(3):CD002817.
34. Deane KH, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. Speech and language therapy for dysarthria in Parkinson's disease. Cochrane Database Syst Rev 2001;(2):CD002812.
35. Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003;84:1109-17.
36. Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2005;86:626-32.
37. Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001;16:79-83.
38. Shimbo T, Goto M, Morimoto T, Hira K, Takemura M, Matsui K, et al. Association between patient education and health-related quality of life in patients with Parkinson's disease. Qual Life Res 2004;13:81-9.